Peter Christian Schlanstein
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Peter Christian Schlanstein has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Jutta Arens
University of Twente
5 shared publications - Niklas Balduin Steuer
Institute of Applied Medical Engineering, Department of Cardiovascular Engineering, Medical Faculty, RWTH Aachen University, 52074 Aachen, Germany
5 shared publications - Thomas Schmitz-Rode
Institute of Applied Medical Engineering Medical Faculty RWTH Aachen University Aachen Germany
5 shared publications - Ulrich Steinseifer
Department of Cardiovascular Engineering, Institute of Applied Medical Engineering University Hospital RWTH Aachen University Aachen Germany
5 shared publications - Sebastian Victor Jansen
Department of Cardiovascular Engineering Institute of Applied Medical Engineering Medical Faculty RWTH Aachen University Aachen Germany
4 shared publications - Felix Hesselmann
Department of Cardiovascular Engineering, Institute of Applied Medical Engineering, Helmholtz Institute, RWTH Aachen University, Aachen, Germany
3 shared publications
Latest Publications
- Open Access
- 31 March 2023
- Published by MDPI AG in Micromachines
- Vol. 14 (4) , 800
Novel Size-Variable Dedicated Rodent Oxygenator for ECLS Animal Models—Introduction of the “RatOx” Oxygenator and Preliminary In Vitro Results
The overall survival rate of extracorporeal life support (ECLS) remains at 60%. Research and development has been slow, in part due to the lack of sophisticated experimental models. This publication introduces a dedicated rodent oxygenator (“RatOx”) and presents preliminary in vitro classification tests. The RatOx has an adaptable fiber module size for various rodent models. Gas transfer performances over the fiber module for different blood flows and fiber module sizes were tested according to DIN EN ISO 7199. At the maximum possible amount of effective fiber surface area and a blood flow of 100 mL/min, the oxygenator performance was tested to a maximum of 6.27 mL O2/min and 8.2 mL CO2/min, respectively. The priming volume for the largest fiber module is 5.4 mL, while the smallest possible configuration with a single fiber mat layer has a priming volume of 1.1 mL. The novel RatOx ECLS system has been evaluated in vitro and has demonstrated a high degree of compliance with all pre-defined functional criteria for rodent-sized animal models. We intend for the RatOx to become a standard testing platform for scientific studies on ECLS therapy and technology.
- 31 March 2023
- Published by MDPI AG in Micromachines
- Vol. 14 (4) , 800
Open AccessNovel Size-Variable Dedicated Rodent Oxygenator for ECLS Animal Models—Introduction of the “RatOx” Oxygenator and Preliminary In Vitro Results
The overall survival rate of extracorporeal life support (ECLS) remains at 60%. Research and development has been slow, in part due to the lack of sophisticated experimental models. This publication introduces a dedicated rodent oxygenator (“RatOx”) and presents preliminary in vitro classification tests. The RatOx has an adaptable fiber module size for various rodent models. Gas transfer performances over the fiber module for different blood flows and fiber module sizes were tested according to DIN EN ISO 7199. At the maximum possible amount of effective fiber surface area and a blood flow of 100 mL/min, the oxygenator performance was tested to a maximum of 6.27 mL O2/min and 8.2 mL CO2/min, respectively. The priming volume for the largest fiber module is 5.4 mL, while the smallest possible configuration with a single fiber mat layer has a priming volume of 1.1 mL. The novel RatOx ECLS system has been evaluated in vitro and has demonstrated a high degree of compliance with all pre-defined functional criteria for rodent-sized animal models. We intend for the RatOx to become a standard testing platform for scientific studies on ECLS therapy and technology.
- Open Access
- 27 February 2023
- Published by MDPI AG in Preprints.org
Novel Size-Variable Dedicated Rodent Oxygenator for ECLS Animal Models: Introduction of the “Ratox” Oxygenator and Preliminary In-Vitro Results
The survival rate of extracorporeal life support (ECLS) remains overall at 60 %. Research and development is slow, partly due to the lack of sophisticated experimental models. This publication introduces a dedicated rodent oxygenator (“RatOx”) and shows preliminary in vitro classification tests. The RatOx has an adaptable fiber module size for various rodent models. Gas transfer performance over the fiber module for different blood flows and fiber module sizes were tested according to DIN EN ISO 7199.At the maximum possible amount of effective fiber surface and a blood flow of 100 ml/min, the oxygenator performance has been tested to a maximum of 6.27 ml O2/min and 8.2 ml CO2/min, respectively. The priming volume for this the largest fiber module is 5.4 ml, while the smallest possible configuration with a single fiber mat layer has 1.1 ml of priming volume. The novel RatOx ECLS system has been evaluated in-vitro to comply to a high degree with all predefined functionality criteria for rodent sized animal models. We intend for the RatOx to become a standard testing platform for scientific studies on ECLS therapy and technology.
- 27 February 2023
- Published by MDPI AG in Preprints.org
Open AccessNovel Size-Variable Dedicated Rodent Oxygenator for ECLS Animal Models: Introduction of the “Ratox” Oxygenator and Preliminary In-Vitro Results
The survival rate of extracorporeal life support (ECLS) remains overall at 60 %. Research and development is slow, partly due to the lack of sophisticated experimental models. This publication introduces a dedicated rodent oxygenator (“RatOx”) and shows preliminary in vitro classification tests. The RatOx has an adaptable fiber module size for various rodent models. Gas transfer performance over the fiber module for different blood flows and fiber module sizes were tested according to DIN EN ISO 7199.At the maximum possible amount of effective fiber surface and a blood flow of 100 ml/min, the oxygenator performance has been tested to a maximum of 6.27 ml O2/min and 8.2 ml CO2/min, respectively. The priming volume for this the largest fiber module is 5.4 ml, while the smallest possible configuration with a single fiber mat layer has 1.1 ml of priming volume. The novel RatOx ECLS system has been evaluated in-vitro to comply to a high degree with all predefined functionality criteria for rodent sized animal models. We intend for the RatOx to become a standard testing platform for scientific studies on ECLS therapy and technology.
- Open Access
In Vitro and In Vivo Feasibility Study for a Portable VV-ECMO and ECCO2R System
Extracorporeal membrane oxygenation (ECMO) is an established rescue therapy for patients with chronic respiratory failure waiting for lung transplantation (LTx). The therapy inherent immobilization may result in fatigue, consecutive deteriorated prognosis, and even lost eligibility for transplantation. We conducted a feasibility study on a novel system designed for the deployment of a portable ECMO device, enabling the physical exercise of awake patients prior to LTx. The system comprises a novel oxygenator with a directly connected blood pump, a double-lumen cannula, gas blender and supply, as well as control and energy management. In vitro experiments included tests regarding performance, efficiency, and blood damage. A reduced system was tested in vivo for feasibility using a novel large animal model. Six anesthetized pigs were first positioned in supine position, followed by a 45° angle, simulating an upright position of the patients. We monitored performance and vital parameters. All in vitro experiments showed good performance for the respective subsystems and the integrated system. The acute in vivo trials of 8 h duration confirmed the results. The novel portable ECMO-system enables adequate oxygenation and decarboxylation sufficient for, e.g., the physical exercise of designated LTx-recipients. These results are promising and suggest further preclinical studies on safety and efficacy to facilitate translation into clinical application.
Open AccessIn Vitro and In Vivo Feasibility Study for a Portable VV-ECMO and ECCO2R System
Extracorporeal membrane oxygenation (ECMO) is an established rescue therapy for patients with chronic respiratory failure waiting for lung transplantation (LTx). The therapy inherent immobilization may result in fatigue, consecutive deteriorated prognosis, and even lost eligibility for transplantation. We conducted a feasibility study on a novel system designed for the deployment of a portable ECMO device, enabling the physical exercise of awake patients prior to LTx. The system comprises a novel oxygenator with a directly connected blood pump, a double-lumen cannula, gas blender and supply, as well as control and energy management. In vitro experiments included tests regarding performance, efficiency, and blood damage. A reduced system was tested in vivo for feasibility using a novel large animal model. Six anesthetized pigs were first positioned in supine position, followed by a 45° angle, simulating an upright position of the patients. We monitored performance and vital parameters. All in vitro experiments showed good performance for the respective subsystems and the integrated system. The acute in vivo trials of 8 h duration confirmed the results. The novel portable ECMO-system enables adequate oxygenation and decarboxylation sufficient for, e.g., the physical exercise of designated LTx-recipients. These results are promising and suggest further preclinical studies on safety and efficacy to facilitate translation into clinical application.
- Open Access
Extracorporeal Hyperoxygenation Therapy (EHT) for Carbon Monoxide Poisoning: In-Vitro Proof of Principle
Carbon monoxide (CO) poisoning is the leading cause of poisoning-related deaths globally. The currently available therapy options are normobaric oxygen (NBO) and hyperbaric oxygen (HBO). While NBO lacks in efficacy, HBO is not available in all areas and countries. We present a novel method, extracorporeal hyperoxygenation therapy (EHT), for the treatment of CO poisoning that eliminates the CO by treating blood extracorporeally at elevated oxygen partial pressure. In this study, we proof the principle of the method in vitro using procine blood: Firstly, we investigated the difference in the CO elimination of a hollow fibre membrane oxygenator and a specifically designed batch oxygenator based on the bubble oxygenator principle at elevated pressures (1, 3 bar). Secondly, the batch oxygenator was redesigned and tested for a broader range of pressures (1, 3, 5, 7 bar) and temperatures (23, 30, 37 °C). So far, the shortest measured carboxyhemoglobin half-life in the blood was 21.32 min. In conclusion, EHT has the potential to provide an easily available and effective method for the treatment of CO poisoning.
Open AccessExtracorporeal Hyperoxygenation Therapy (EHT) for Carbon Monoxide Poisoning: In-Vitro Proof of Principle
Carbon monoxide (CO) poisoning is the leading cause of poisoning-related deaths globally. The currently available therapy options are normobaric oxygen (NBO) and hyperbaric oxygen (HBO). While NBO lacks in efficacy, HBO is not available in all areas and countries. We present a novel method, extracorporeal hyperoxygenation therapy (EHT), for the treatment of CO poisoning that eliminates the CO by treating blood extracorporeally at elevated oxygen partial pressure. In this study, we proof the principle of the method in vitro using procine blood: Firstly, we investigated the difference in the CO elimination of a hollow fibre membrane oxygenator and a specifically designed batch oxygenator based on the bubble oxygenator principle at elevated pressures (1, 3 bar). Secondly, the batch oxygenator was redesigned and tested for a broader range of pressures (1, 3, 5, 7 bar) and temperatures (23, 30, 37 °C). So far, the shortest measured carboxyhemoglobin half-life in the blood was 21.32 min. In conclusion, EHT has the potential to provide an easily available and effective method for the treatment of CO poisoning.
- Open Access
- 21 June 2021
- Published by Springer Nature in Bio-Design and Manufacturing
- Vol. 5 (1) , 141-152
Introducing 3D-potting: a novel production process for artificial membrane lungs with superior blood flow design
Currently, artificial-membrane lungs consist of thousands of hollow fiber membranes where blood flows around the fibers and gas flows inside the fibers, achieving diffusive gas exchange. At both ends of the fibers, the interspaces between the hollow fiber membranes and the plastic housing are filled with glue to separate the gas from the blood phase. During a uniaxial centrifugation process, the glue forms the “potting.” The shape of the cured potting is then determined by the centrifugation process, limiting design possibilities and leading to unfavorable stagnation zones associated with blood clotting. In this study, a new multiaxial centrifugation process was developed, expanding the possible shapes of the potting and allowing for completely new module designs with potentially superior blood flow guidance within the potting margins. Two-phase simulations of the process in conceptual artificial lungs were performed to explore the possibilities of a biaxial centrifugation process and determine suitable parameter sets. A corresponding biaxial centrifugation setup was built to prove feasibility and experimentally validate four conceptual designs, resulting in good agreement with the simulations. In summary, this study shows the feasibility of a multiaxial centrifugation process allowing greater variety in potting shapes, eliminating inefficient stagnation zones and more favorable blood flow conditions in artificial lungs. Graphic abstract
- 21 June 2021
- Published by Springer Nature in Bio-Design and Manufacturing
- Vol. 5 (1) , 141-152
Open AccessIntroducing 3D-potting: a novel production process for artificial membrane lungs with superior blood flow design
Currently, artificial-membrane lungs consist of thousands of hollow fiber membranes where blood flows around the fibers and gas flows inside the fibers, achieving diffusive gas exchange. At both ends of the fibers, the interspaces between the hollow fiber membranes and the plastic housing are filled with glue to separate the gas from the blood phase. During a uniaxial centrifugation process, the glue forms the “potting.” The shape of the cured potting is then determined by the centrifugation process, limiting design possibilities and leading to unfavorable stagnation zones associated with blood clotting. In this study, a new multiaxial centrifugation process was developed, expanding the possible shapes of the potting and allowing for completely new module designs with potentially superior blood flow guidance within the potting margins. Two-phase simulations of the process in conceptual artificial lungs were performed to explore the possibilities of a biaxial centrifugation process and determine suitable parameter sets. A corresponding biaxial centrifugation setup was built to prove feasibility and experimentally validate four conceptual designs, resulting in good agreement with the simulations. In summary, this study shows the feasibility of a multiaxial centrifugation process allowing greater variety in potting shapes, eliminating inefficient stagnation zones and more favorable blood flow conditions in artificial lungs. Graphic abstract